A risankizumab super responder profile identified by long‐term <scp>real‐life</scp> observation‐<scp>IL PSO</scp> (<scp>ITALIAN LANDSCAPE PSORIASIS</scp>)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Francesca Sampogna, Massimo Travaglini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Abstract
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
MedicinePsoriasisTerm (time)ImmunologyQuantum mechanicsPhysicsMultiple Sclerosis Research StudiesRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis